Hermes Pharma, a German Contract Development and Manufacturing Organization (CDMO), has announced a significant investment of 25 million euros ($26 million) aimed at enhancing its manufacturing capabilities for oral medications. This financial commitment will be allocated towards the acquisition of new equipment, streamlining operational efficiency, expanding production capacity, and increasing storage facilities, as detailed in a press release issued on September 26.
“As pharmaceutical companies race to find ways to better serve patients and differentiate themselves in a competitive market, we’re seeing unprecedented demand for more patient-centric products. Our latest investment will help us meet that demand, delivering ever greater service for our customers, while also helping us serve new customers across different market segments. We look forward to getting new and improved user-friendly dosage forms to patients quickly and more efficiently than ever before.”
– Dr Andreas Ulrich, COO of Hermes Pharma
Also Read: What’s Behind Emergent BioSolutions’ Decision To Lay Off 400 Employees And Eliminate An Executive Role?
The strategic investment is anticipated to fuel future growth for Hermes Pharma, a company recognized for its expertise in producing patient-friendly oral dosage forms, including orally disintegrating granules and chewable tablets.
In an industry marked by fierce competition and a heightened focus on patient-centric solutions, pharmaceutical companies are actively seeking ways to enhance patient experiences. This has led to an unprecedented demand for user-friendly medication formats.
Hermes Pharma, established in 1907 and headquartered in Pullach, Germany, operates in close association with Hermes Arzneimittel, a company renowned for marketing over-the-counter (OTC) brands. Hermes Pharma, in particular, positions itself as a CDMO specialized in the development and production of patient-centric dosage forms.
The company has established partnerships with half of the top 20 pharmaceutical companies globally, in addition to collaborating with four leading players in the generics sector. This strategic investment is poised to solidify Hermes Pharma’s position in the pharmaceutical manufacturing landscape and enable it to continue serving the evolving needs of the industry.
